Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Sorafenib in hepatocellular carcinoma: separating the hype from the hope.

Kelley RK, Venook AP.

J Clin Oncol. 2008 Dec 20;26(36):5845-8. doi: 10.1200/JCO.2008.19.7996. Epub 2008 Nov 24. No abstract available.

PMID:
19029408
2.

Selection of patients with hepatocellular carcinoma for sorafenib.

Abou-Alfa GK.

J Natl Compr Canc Netw. 2009 Apr;7(4):397-403. Review.

PMID:
19406040
3.

[Chemotherapy].

Ikeda M, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Okusaka T.

Gan To Kagaku Ryoho. 2010 Mar;37(3):408-12. Review. Japanese.

PMID:
20332676
4.

Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?

Burak KW.

Oncology (Williston Park). 2011 Mar;25(3):296, 298, 300. Review. No abstract available.

PMID:
21548474
5.

Sorafenib: in hepatocellular carcinoma.

Simpson D, Keating GM.

Drugs. 2008;68(2):251-8. Review.

PMID:
18197728
6.

[Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].

Greten TF, Manns MP, Malek N.

Z Gastroenterol. 2009 Jan;47(1):55-60. doi: 10.1055/s-0028-1109067. Epub 2009 Jan 20. Review. German.

PMID:
19156592
7.

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R.

Oncologist. 2009 Jan;14(1):95-100. doi: 10.1634/theoncologist.2008-0185. Epub 2009 Jan 14. Review.

8.

[Hepatocellular carcinoma].

Yamashita T, Arai K, Kaneko S.

Nihon Rinsho. 2010 Oct;68(10):1861-5. Review. Japanese.

PMID:
20954330
9.

Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.

Yau T, Pang R, Chan P, Poon RT.

Expert Opin Pharmacother. 2010 Sep;11(13):2187-98. doi: 10.1517/14656561003724705. Review.

PMID:
20707757
10.

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

Zhu AX.

Expert Opin Investig Drugs. 2010 May;19(5):663-72. doi: 10.1517/13543781003767426. Review.

PMID:
20367287
11.

Sorafenib: delivering a targeted drug to the right targets.

Flaherty KT.

Expert Rev Anticancer Ther. 2007 May;7(5):617-26. Review.

PMID:
17492926
12.

[Use of sorafenib in patients with hepatocellular or renal carcinoma].

Rosmorduc O, Chevreau C, Dielenseger P, Ederhy S, Goldwasser F, Grange JD, Mortier L, Neidhardt-Berard ME, Robert C, Scotté F, Seitz JF.

Gastroenterol Clin Biol. 2010 Mar;34(3):161-7. doi: 10.1016/j.gcb.2009.12.004. Epub 2010 Feb 23. Review. French.

13.

What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.

Kim R, Byrne MT, Tan A, Aucejo F.

Oncology (Williston Park). 2011 Mar;25(3):283-91, 295. Review.

14.

[The hepatocellular carcinoma: alternative therapeutical strategies].

Spangenberg HC, Thimme R, Mohr L, Blum HE.

Zentralbl Chir. 2007 Aug;132(4):322-7. Review. German.

PMID:
17724635
15.

Sorafenib for HCC: a pragmatic perspective.

Razumilava N, Gores GJ.

Oncology (Williston Park). 2011 Mar;25(3):300, 302. Review. No abstract available.

16.

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.

Carr BI, Carroll S, Muszbek N, Gondek K.

J Gastroenterol Hepatol. 2010 Nov;25(11):1739-46. doi: 10.1111/j.1440-1746.2010.06404.x. Review.

PMID:
21039835
17.

Sorafenib in hepatocellular carcinoma.

Josephs DH, Ross PJ.

Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. Review.

PMID:
20852487
18.

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Keating GM, Santoro A.

Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. Review.

PMID:
19228077
19.

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

Cabibbo G, Rolle E, De Giorgio M, Genco C, Pressiani T, Spada F, Sacco R; HCC Working Group.

Expert Rev Anticancer Ther. 2011 Dec;11(12):1807-16. doi: 10.1586/era.11.139. Epub 2011 Aug 26. Review.

PMID:
22049974
20.

Sorafenib for advanced hepatocellular carcinoma: a systematic review.

Ling-lin Z, Li M, Jin-hui T, Ke-hu Y.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Feb;33(1):51-7. doi: 10.3881/j.issn.1000-503X.2011.01.011. Review.

Supplemental Content

Support Center